Aarti Drugs Limited convened a Board of Directors meeting on August 27, 2026, as disclosed to the National Stock Exchange, with the outcome formally communicated at 12:45 PM. The announcement follows a period of notable shareholder reward activity, with the company having declared an interim dividend of ₹2 per equity share at its February 3, 2026 board meeting, doubling the payout from the prior year's ₹1 per share.

Dividend Details and Yield

The February 2026 interim dividend of ₹2 per equity share (face value ₹10) represents a payout ratio of 20% on face value. With NSE quote data unavailable at the time of publication, a precise trailing dividend yield cannot be calculated. However, investors should note that at the stock's last known trading range, the ₹2 dividend represents the highest per-share interim payout declared by the company since October 2020, when it paid ₹2.5 per share in a one-time mid-year distribution tied to an exceptional earnings cycle during the COVID-19 API demand surge.

Dividend History and Trend Analysis

A review of Aarti Drugs' dividend history over the past decade reveals a clear pattern of consistent, if modest, payouts with a recent step-up:

The data shows that from FY2022 through FY2025, Aarti Drugs maintained a flat interim dividend of ₹1 per share for four consecutive years. The doubling to ₹2 per share in February 2026 breaks this plateau and signals improved cash generation confidence at the board level. The timing shift from final dividends (pre-2020) to interim dividends (post-2020) also reflects a structural change in the company's capital return calendar, with payouts now consistently announced in the January-February window each year.

Company Background

Aarti Drugs Limited, listed on NSE under the symbol AARTIDRUGS (ISIN: INE767A01016), is a Mumbai-based active pharmaceutical ingredient (API) and intermediate manufacturer. The company supplies APIs across therapeutic segments including anti-infectives, cardiovascular, and anti-diabetic categories to both domestic formulators and export markets. It operates as part of the broader Aarti group of companies.

What This Means for Investors

The August 27, 2026 board meeting outcome, while not specifying the agenda in the available disclosure, occurs against the backdrop of a company that has materially improved its dividend per share in the most recent cycle. The 100% year-on-year increase in interim dividend from ₹1 to ₹2 per share is a data point that income-oriented investors tracking the pharmaceutical API space will find relevant when assessing capital allocation discipline. Investors are advised to monitor the formal outcome disclosure for details on any additional financial decisions taken at the August 27 meeting, including any interim dividend declaration for FY2027, which would follow the company's established January-February announcement pattern.